- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jason Harris | Authors
Promising EFS Noted Following Neoadjuvant Nivo/Chemo in Resectable NSCLC Following pCR
July 01, 2022
Patients with stage IB to IIA non–small cell lung cancer who experienced a pathologic complete response to neoadjuvant nivolumab plus platinum-based doublet chemotherapy experienced a prolonged event-free survival.
Patritumab Deruxtecan Yields Positive Response Rates in HER3-Expressing Metastatic Breast Cancer
June 05, 2022
Patritumab deruxtecan induced positive efficacy, according to the phase 1/2 U31402-J101 trial in patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.
Hispanic Patients With Pediatric Neuroblastoma May Have Worse OS Outcomes vs Other Ethnic Subgroups
May 27, 2022
Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.
Response Prediction May Be Possible With Baseline Characteristics in Multiple Myeloma
April 25, 2022
The phase 2 KarMMA trial showed that certain characteristics were potentially linked to complete responses in patients with multiple myeloma.
Reduction in GVHD and Prednisone Use With Abatacept Observsed After Stem Cell Transplant
April 24, 2022
A phase 2 trial reported a reduction in steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant.
Improved Responses to Talazoparib Associated With gLOH Status in mCRPC
April 12, 2022
Patients with metastatic castration-resistant prostate cancer who had a high genomic loss of heterozygosity may respond better to treatment with talazoparib.
AMF13 Plus Natural Killer Cells Produced Encouraging Early Responses in Heavily Pretreated Lymphoma
April 10, 2022
Investigators of a phase 1/2 trial observed positive response outcomes with expanded natural killer cells plus AMF13 in patients with heavily pretreated lymphoma.
Evidence Shows Novel Temferon May Have Activity in Glioblastoma
April 09, 2022
Early findings from the phase 1/2a TEM-GBM study presented at the 2022 AACR Annual Meeting displayed potential of temferon to affect the tumor microenvironment of glioblastoma.
Early Activity of Neoadjuvant Niraparib in HRD+ Ovarian Cancer Reported in NANT Trial
March 19, 2022
Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.
Phase 2 Trial Launched of Anlotinib Plus Sintilimab in China for OCCC
March 18, 2022
The phase 2 CC-ANNIE trial was launched in China investigating anlotinib plus sintilimiab for recurrent platinum-resistant ovarian clear cell carcinoma.